Company Name
Immunovant Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US45258J1025
CIK:
0001764013
CUSIP:
45258J201
Currency:
USD
Full Time Employees:
315
Phone:
917 410 3120
Website:
https://immunovant.com
Fiscal Year End:
March
IPO Date:
Jun 21, 2019
Description:
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Address:
1000 Park Forty Plaza, Durham, NC, United States, 27713